Bora Pharmaceuticals Co. Ltd., a pharmaceutical manufacturer, has announced plans to add further sterile fill/finish capacity at its facility in Baltimore, Maryland.

Installation of a new AST GENiSYS C automated vial, syringe and cartridge line will take place over the course of the next year. The new line will operate under full isolator conditions and is ideally suited for clinical and small-scale commercial supply for high-value substances.

“Bora is more frequently seeing demand for drug product fill and finish of potent drug candidates and approved treatments, as well as for rare and orphan diseases,” commented J.D. Mowery, President of Bora’s CDMO Division. “The addition of a precision small-scale isolator line adds to our overall capacity, and working in concert with our existing large-scale lines, increases our flexibility and scalability. I look forward to adding to our capabilities in the U.S. so that we remain ready to meet rising demand from clients, both domestic and international.”

Bora’s 87,000-sq. ft. Baltimore facility provides drug product manufacturing services for sterile injectables and offers clinical and commercial non-viral aseptic fill/finish services for vials and pre-filled syringes on four fill lines, in addition to lyophilization, terminal sterilization, analytical, stability, packaging and serialization, and additional support services.

Earlier this month, Bora also announced plans to expand its  U.S. FDA-registered commercial manufacturing facility in San Diego.